Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity

Abstract

Objectives

To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).

Method

37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).

Results

Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).

Conclusion

The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

Keywords

soluble receptor inflammatory markers cytokines biomarker advanced glycation

Get full access to this article

View all access options for this article.

References

1 Bucciarelli LG Wendt T Rong L . RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. [Review] Cell Mol Life Sci 2002; 59: 1117 – 1128 .

2 Stern DM Yan SD Yan SF Schmidt AM . Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. [Review] Ageing Res Rev 2002; 1: 1 – 15 .

3 Yan SD Chen X Fu J . RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685 – 691 .

4 Hofmann MA Drury S Fu C . RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889 – 901 .

5 Hori O Brett J Slattery T . The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752 – 25761 .

6 Chavakis T Bierhaus A Al-Fakhri N . The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507 – 1515 .

7 Brett J Schmidt AM Yan SD . Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699 – 1712 .

8 Mene P Festuccia F Pugliese F . Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus. [Review] Am J Cardiovasc Drugs 2003; 3: 315 – 320 .

9 Ramasamy R Vannucci SJ Yan SS . Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. [Review] Glycobiology 2005; 15: 16R – 28R .

10.

10 Yan SS Wu ZY Zhang HP . Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003; 9: 287 – 293 .

11.

11 Arancio O Zhang HP Chen X . RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004; 23: 4096 – 4105 .

12.

12 Sunahori K Yamamura M Yamana J . Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006; 54: 97 – 104 .

13.

13 Emanuele E D'Angelo A Tomaino C . Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62: 1734 – 1736 .

14.

14 Pullerits R Bokarewa M Dahlberg L Tarkowski A . Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7: R817 – R824 .

15.

15 Basta G Sironi AM Lazzerini G . Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and A12 protein. J Clin Endocrinol Metab 2006; 91: 4628 – 4634 .

16.

16 Falcone C Emanuele E D'Angelo A . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler, Thromb & Vasc Biol 2005; 25: 1032 – 1037 .

17.

17 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121 – 127 .

18.

18 Jinnouchi Y Yamagishi S Takeuchi M . Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191 – 193 .

19.

19 Gu L Ni Z Qian J . Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol 2007; 106: e1 – 10 .

20.

20 Cuccurullo C Iezzi A Fazia ML . Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler, Thromb & Vasc Biol 2006; 26: 2716 – 2723 .

21.

21 Tanaka N Yonekura H Yamagishi S . The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781 – 25790 .

22.

22 Nguyen LT Ramanathan M Weinstock-Guttman B . Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003; 209: 93 – 99 .

23.

23 Schmidt AM Yan SD Yan SF . The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. [Review] J Clin Invest 2001; 108: 949 – 955 .

24.

24 Vos CM Geurts JJ Montagne L . Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005; 20: 953 – 960 .

25.

25 Kraus J Oschmann P . The impact of interferon-beta treatment on the blood-brain barrier. [Review]. Drug Discov Today 2006; 11: 755 – 762 .

26.

26 Thompson AJ . Polman CH. Miller DH. McDonald WI. Brochet B. Filippi M, et al. Primary progressive multiple sclerosis. [Review] Brain 1997; 120: 1085 – 1096 .

27.

27 Geroldi D Falcone C Emanuele E . Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. [Review] Curr Med Chem 2006; 13: 1971 – 1978 .